559 related articles for article (PubMed ID: 23254142)
1. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.
Zhao W; Lopez E; Biran V; Durrmeyer X; Fakhoury M; Jacqz-Aigrain E
Arch Dis Child; 2013 Jun; 98(6):449-53. PubMed ID: 23254142
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin prescription in neonates and young infants: toward a simplified dosage.
Oudin C; Vialet R; Boulamery A; Martin C; Simon N
Arch Dis Child Fetal Neonatal Ed; 2011 Sep; 96(5):F365-70. PubMed ID: 21378399
[TBL] [Abstract][Full Text] [Related]
5. Neonatal vancomycin continuous infusion: still a confusion?
Gwee A; Cranswick N; Metz D; Coghlan B; Daley AJ; Bryant PA; Curtis N
Pediatr Infect Dis J; 2014 Jun; 33(6):600-5. PubMed ID: 24378952
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
7. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
[TBL] [Abstract][Full Text] [Related]
9. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
Eiland LS; English TM; Eiland EH
Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
[TBL] [Abstract][Full Text] [Related]
10. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.
Kato H; Hagihara M; Nishiyama N; Koizumi Y; Mikamo H; Matsuura K; Yamagishi Y
J Infect Chemother; 2017 Mar; 23(3):154-160. PubMed ID: 28017667
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion.
De Waele JJ; Danneels I; Depuydt P; Decruyenaere J; Bourgeois M; Hoste E
Int J Antimicrob Agents; 2013 May; 41(5):434-8. PubMed ID: 23410793
[TBL] [Abstract][Full Text] [Related]
12. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.
Plan O; Cambonie G; Barbotte E; Meyer P; Devine C; Milesi C; Pidoux O; Badr M; Picaud JC
Arch Dis Child Fetal Neonatal Ed; 2008 Nov; 93(6):F418-21. PubMed ID: 18450803
[TBL] [Abstract][Full Text] [Related]
13. [Level of evidence for therapeutic drug monitoring of vancomycin].
Jelassi ML; Benlmouden A; Lefeuvre S; Mainardi JL; Billaud EM;
Therapie; 2011; 66(1):29-37. PubMed ID: 21466775
[TBL] [Abstract][Full Text] [Related]
14. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study.
Li J; Udy AA; Kirkpatrick CM; Lipman J; Roberts JA
Int J Antimicrob Agents; 2012 Jan; 39(1):69-72. PubMed ID: 22024354
[TBL] [Abstract][Full Text] [Related]
15. [Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data].
Xu G; Chen E; Mao E; Che Z; He J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):640-645. PubMed ID: 30045790
[TBL] [Abstract][Full Text] [Related]
16. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy.
Beumier M; Roberts JA; Kabtouri H; Hites M; Cotton F; Wolff F; Lipman J; Jacobs F; Vincent JL; Taccone FS
J Antimicrob Chemother; 2013 Dec; 68(12):2859-65. PubMed ID: 23800905
[TBL] [Abstract][Full Text] [Related]
17. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring in neonates.
Pauwels S; Allegaert K
Arch Dis Child; 2016 Apr; 101(4):377-81. PubMed ID: 26803050
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and dose requirements of vancomycin in neonates.
Grimsley C; Thomson AH
Arch Dis Child Fetal Neonatal Ed; 1999 Nov; 81(3):F221-7. PubMed ID: 10525029
[TBL] [Abstract][Full Text] [Related]
20. Tobramycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 1997 Oct; 62(4):392-9. PubMed ID: 9357390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
